ZYUS Life Sciences Ships Medical Cannabinoid Oil Formulations for Distribution in Australia
SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences firm main scientific analysis and improvement in phyto-therapeutics, has accomplished its first worldwide cargo of ZYUS’ first-generation cannabinoid oil formulations to the Australian medical hashish market in preparation for the gross sales and distribution beneath Australia’s Therapeutic Items Act (“TGA”) particular entry and licensed prescriber scheme. By means of ZYUS’ Australian distributor, the corporate’s first-generation cannabinoid oil formulations can be accessible by means of roughly 4,300 pharmacies throughout Australia as physicians are launched to ZYUS’ medical cannabinoid formulations. This achievement marks an necessary milestone in ZYUS’ mission to enhance high quality of life for thousands and thousands of sufferers exterior of Canada by means of plant-made therapeutics – leveraging cannabinoids and their transformational potential.
Australia is the primary worldwide market to obtain ZYUS’ first-generation cannabinoid oil formulations, with the corporate planning to export its first-generation medical cannabinoid merchandise to extra markets in accordance with pharmaceutical distribution and gross sales agreements it at the moment has in place with varied worldwide distributors. Three of ZYUS’ first-generation cannabinoid oil formulations, together with Zylem 1:20 Oil (excessive CBD), Zylem 10:10 Oil (balanced CBD/THC), and Zylem 20:1 Oil (excessive THC), can be accessible by means of pharmacies throughout Australia as the corporate begins to scale its distribution community.
Along with initiating distribution of ZYUS’ first-generation cannabinoid oil formulations in Australia, ZYUS continues to advance its analysis actions and has performed its Part One Human Osteoarthritis Ache Analysis (HOPE) scientific trial in Australia. The formulation being studied, Trichomylin® softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate power ache and has the potential to be a secure and efficient different to opioids – with out the devasting addictive qualities. ZYUS’ second-generation drug product candidates, together with Trichomylin® softgels, will solely be out there to sufferers by prescription as soon as it undergoes the required scientific trials and receives regulatory approval as a drug product.
“At ZYUS, we consider there is no such thing as a mission extra necessary than to enhance high quality of life for the thousands and thousands affected by power and sustained medical situations.” mentioned ZYUS CEO Brent Zettl “This primary worldwide cargo of cannabinoid oil formulations to Australia marks an necessary step in ZYUS’ journey to enhance a rising variety of affected person outcomes, and one other milestone within the firm’s plans for world growth.”
High quality in Manufacturing
ZYUS manufactures its cannabinoid extracts in an business main, pharmaceutical-grade extraction facility, with all merchandise present process rigorous testing and greater than 450 factors of high quality management to make sure manufacturing of standardized formulations that sufferers and healthcare practitioners can depend on. ZYUS was lately awarded EU-Good Manufacturing Apply (EU-GMP) certification for its Canadian manufacturing facility, enabling the corporate to execute upon its well-developed plans for growth into numerous key worldwide markets.
Ahead-Trying Data:
This information launch comprises forward-looking statements. Ahead-looking statements contain recognized and unknown dangers, uncertainties and different components which can trigger the precise outcomes, efficiency or achievements of ZYUS to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements. These forward-looking statements embrace, however are usually not restricted to, expectations with respect to our enterprise plans, analysis actions, product strains and efficacy and affected person providers.
Typically, however not all the time, forward-looking statements will be recognized by way of phrases equivalent to “expects,” “anticipated,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “focused,” “plans,” “potential” and comparable expressions, or statements that occasions, situations or outcomes “will,” “could,” “might,” “would” or “ought to” happen or be achieved, or the adverse of those phrases or different comparable terminology. Ahead-looking statements are primarily based on sure assumptions together with assumptions regarding the flexibility of ZYUS to proceed to make sure product availability, consistency and high quality by means of sturdy procurement, manufacturing and testing processes, and are topic to numerous recognized and unknown dangers and uncertainties, lots of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. These dangers embrace the danger that ZYUS is unable to proceed to export its merchandise internationally, safe regulatory approvals of its formulations, guarantee product availability, consistency and high quality by means of sturdy procurement, manufacturing and testing processes.
Accordingly, readers mustn’t place undue reliance on the forward-looking statements and data contained on this press launch. Since forward-looking statements and data handle future occasions and situations, by their very nature they contain inherent dangers and uncertainties.
Readers are cautioned that the foregoing record of things isn’t exhaustive. The forward-looking statements contained on this information launch are made as of the date of this launch and, accordingly, are topic to vary after such date. ZYUS doesn’t assume any obligation to replace or revise any forward-looking statements or data, whether or not written or oral, that could be made now and again by us or on our behalf, besides as required by relevant legislation.
